O	0	9	Improving
O	10	19	awareness
O	19	20	,
O	21	35	identification
O	35	36	,
O	37	40	and
O	41	51	management
O	52	54	of
B-Disease	55	64	meibomian
I-Disease	65	70	gland
I-Disease	71	82	dysfunction
O	82	83	.

B-Disease	85	91	Ocular
I-Disease	92	99	surface
I-Disease	100	108	disorder
O	108	109	-
O	109	110	-
O	110	113	and
B-Disease	114	117	dry
I-Disease	118	121	eye
O	121	122	,
O	123	125	in
O	126	136	particular
O	136	137	-
O	137	138	-
O	138	140	is
O	141	142	a
O	143	150	leading
O	151	157	reason
O	158	161	for
O	162	168	visits
O	169	171	to
B-Anatomy	172	175	eye
O	176	180	care
O	181	194	professionals
O	194	195	.

O	196	198	It
O	199	202	has
O	203	207	been
O	208	217	generally
O	218	226	accepted
O	227	231	that
B-Disease	232	241	meibomian
I-Disease	242	247	gland
I-Disease	248	259	dysfunction
O	260	261	(
B-Disease	261	264	MGD
O	264	265	)
O	266	268	is
O	269	270	a
O	271	278	leading
O	279	284	cause
O	285	287	of
B-Disease	288	299	evaporative
I-Disease	300	303	dry
I-Disease	304	307	eye
O	307	308	,
O	309	311	as
O	312	316	well
O	317	319	as
O	320	325	being
O	326	336	associated
O	337	341	with
B-Disease	342	349	aqueous
I-Disease	349	350	-
I-Disease	350	359	deficient
I-Disease	360	363	dry
I-Disease	364	367	eye
O	367	368	.

O	369	372	Yet
O	372	373	,
O	374	385	researchers
O	386	389	and
O	390	400	clinicians
O	401	405	have
O	406	412	lacked
O	413	414	a
O	415	421	global
O	422	431	consensus
O	432	434	on
O	435	438	the
O	439	449	definition
O	450	452	of
B-Disease	453	456	MGD
O	456	457	,
O	458	461	its
O	462	474	epidemiology
O	474	475	,
O	476	491	pathophysiology
O	491	492	,
O	493	496	and
O	497	507	management
O	507	508	.

O	509	516	Various
O	517	525	systemic
O	526	534	diseases
O	535	538	and
O	539	550	medications
O	551	555	have
O	556	560	been
O	561	571	associated
O	572	576	with
O	577	580	the
O	581	592	progression
O	593	595	of
O	596	600	both
B-Disease	601	604	dry
I-Disease	605	608	eye
O	609	612	and
B-Disease	613	616	MGD
O	616	617	,
O	618	620	as
O	621	625	have
O	626	633	several
B-Disease	634	640	ocular
I-Disease	641	650	disorders
O	651	657	beyond
O	658	663	those
O	664	672	directly
O	673	682	affecting
O	683	686	the
O	687	694	surface
O	694	695	.

O	696	698	It
O	699	701	is
O	702	704	in
O	705	708	the
O	709	713	best
O	714	722	interest
O	723	725	of
O	726	734	patients
O	735	738	for
O	739	749	clinicians
O	750	752	to
O	753	755	be
O	756	760	able
O	761	763	to
O	764	770	better
O	771	779	identify
O	780	783	and
O	784	792	diagnose
B-Disease	793	796	MGD
O	796	797	,
O	798	813	differentiating
O	814	816	it
O	817	821	from
O	822	827	other
B-Disease	828	834	ocular
I-Disease	835	842	surface
I-Disease	843	852	disorders
O	852	853	,
O	854	857	and
O	858	860	to
O	861	870	recognize
O	871	874	the
O	875	882	effects
O	883	885	of
B-Disease	886	889	MGD
O	890	892	on
O	893	896	the
B-Anatomy	897	903	ocular
I-Anatomy	904	911	surface
O	911	912	,
O	913	916	and
O	917	921	thus
O	922	930	initiate
O	931	942	appropriate
O	943	950	therapy
O	950	951	.

O	952	956	This
O	957	960	CME
O	961	969	activity
O	970	978	provides
O	979	985	expert
O	986	993	insight
O	994	998	into
O	999	1002	the
O	1003	1007	Tear
O	1008	1012	Film
O	1013	1016	and
O	1017	1023	Ocular
O	1024	1031	Surface
O	1032	1039	Society
O	1039	1040	'
O	1040	1041	s
O	1042	1055	International
O	1056	1064	Workshop
O	1065	1067	on
B-Disease	1068	1071	MGD
O	1072	1081	consensus
O	1082	1088	report
O	1088	1089	,
O	1090	1098	offering
O	1099	1108	practical
O	1109	1120	application
O	1121	1123	of
O	1124	1127	its
O	1128	1136	findings
O	1137	1139	to
O	1140	1146	better
O	1147	1153	manage
B-Disease	1154	1157	MGD
O	1158	1165	patient
O	1166	1170	care
O	1170	1171	,
O	1172	1184	particularly
O	1185	1188	for
O	1189	1194	those
O	1195	1203	patients
O	1204	1210	facing
O	1211	1213	or
O	1214	1224	undergoing
B-Anatomy	1225	1231	ocular
O	1232	1239	surgery
O	1239	1240	.
